Eloralintide 10mg Peptide
For in-vitro laboratory research only. Not for human or animal administration.
Batch #: VPEL10100
Get Notified When Available
This product is currently out of stock. Enter your email and we'll notify you the moment it's back.
Research Use Only
For in-vitro laboratory research by qualified professionals only. Not for human or animal administration. Not a drug, food, cosmetic or dietary supplement. Not intended to diagnose, treat, cure, mitigate or prevent any disease. Batch-specific Certificates of Analysis available for all products.
Eloralintide 10mg: overview
What the vial contains and what the material is, stated as specifications rather than as outcomes.
Eloralintide supplied as a lyophilized powder in a sealed single-use vial containing 10 mg of material. Released to a specification of >99% purity by HPLC. Soluble in bacteriostatic water. Supplied for in-vitro laboratory research only. Not a drug, food or supplement. Not for human or veterinary use.
Volta does not provide dosing, administration or protocol guidance for any material listed.
Eloralintide 10mg specifications
Every field the product record holds. A field with no value is omitted rather than printed as a dash.
- Fill
- 10mg
- Form
- Lyophilized powder
- Solubility
- Soluble in bacteriostatic water
- Shelf life
- 24 months from date of manufacture
Eloralintide analytical verification and batch documentation
What the purity figure on this page is, who measured what, and which of the two a reader is looking at.
Specification. Every batch is released to >99% purity by HPLC. That is a threshold Volta sets, and it is a promise rather than a measurement.
Measurement. No certificate for this compound is published on the site yet. A batch-specific Certificate of Analysis is available on request, and the batch history lists the ones already published. Until one is published for this material, the figure above is the release specification and nothing on this page is a laboratory result.
Checking a certificate. The batch number printed beside the price is derived from the compound code and the vial strength; the lot number on a certificate is transcribed from the document. They are produced independently, so comparing them is a real check. How to read one is set out in the quality and testing methodology page.
For in-vitro laboratory research by qualified professionals only. Not for human or animal administration. Not a drug, food, cosmetic or dietary supplement. Not intended to diagnose, treat, cure, mitigate or prevent any disease.
Amylin is co-secreted with insulin from pancreatic beta cells and acts in the area postrema to signal meal termination. Eloralintide is one of the newest entrants in the selective amylin agonist class, and interest in it stems from the hypothesis that amylin pathway activation produces weight effects with a different tolerability profile than incretin agonism, and may be additive to it. Because the compound is recent and much of its clinical dataset is not yet published, it is treated as an early-stage research material. This 10mg vial supports receptor-binding and comparative in vitro work against cagrilintide and pramlintide.
- Released to a >99% purity specification by HPLC
- Lyophilized powder, 10mg per vial
- Soluble in bacteriostatic water
- For laboratory research use only
Frequently Bought Together
Eloralintide 10mg
10mg
$99 USD
Bundle & Save
$196 USD
Save $9.80 USD
$259 USD
Save $25.90 USD
$308 USD
Save $46.20 USD
$392 USD
Save $78.40 USD
Click any product above to toggle selection
Related research materials
Eloralintide 10mg: what is in the vial
The arithmetic specific to this 10mg vial, and what a milligram of Eloralintide costs in each strength the catalogue carries. Concentrations are stated, not recommended.
Vial contents
10 mg
Lyophilised powder, reconstituted by the buyer
Cost of material
$9.90 / mg USD
CA$14.10 / mg in Canadian dollars
Concentration at each diluent volume
10 mg of dry material reaches these concentrations in the volumes below. A U-100 syringe marking is 0.01 ml by definition, so the last column is a unit conversion at each concentration rather than a quantity to use.
| Diluent added | Concentration | In 0.1 ml | Per U-100 unit |
|---|---|---|---|
| 1 ml | 10 mg/ml | 1 mg | 100 mcg |
| 2 ml | 5 mg/ml | 500 mcg | 50 mcg |
| 3 ml | 3.33 mg/ml | 333.3 mcg | 33.3 mcg |
| 5 ml | 2 mg/ml | 200 mcg | 20 mcg |
For a volume this table does not list, the reconstitution calculator takes any vial size and diluent volume.
Eloralintide purity and identity: how the figure is measured
What >99% (HPLC) means, the masses an identity check has to land on, and the entries that make a certificate of analysis checkable rather than decorative.
Stated purity
>99% (HPLC)
Area percent of the main peak by reversed-phase HPLC
What a certificate for Eloralintide should carry
A purity percentage on its own is not checkable. These are the entries that make one verifiable, and their absence is the most common weakness in a research-peptide certificate.
The chromatogram, not only the number
A stated area percent with no trace behind it cannot be read for the shape of the main peak or for what eluted beside it. The HPLC interpreter walks through what a trace shows.
Net peptide content, separately from gross mass
A lyophilised peptide is a salt, usually of trifluoroacetic or acetic acid, plus residual water. The vial's stated milligrams are gross; net peptide content is the fraction of that mass which is the molecule. The two differ by ten to twenty percent routinely, and only one of them is what the price is per milligram of. The net peptide content calculator converts between them.
The counterion, named
Which salt form the powder is in changes the net content and the pH the powder dissolves at. A certificate that never names it leaves both unknowable.
Water content, by a stated method
Loss on drying and Karl Fischer titration give different numbers, and a water figure with no method attached cannot be compared with anyone else's.
A laboratory and a report identifier
Without both, nothing on the document can be traced back to the laboratory that issued it. The red flag checker lists the rest.
Batch certificates are published as page images in the certificate library. The source PDFs are never served: a certificate is the most forgeable document a supplier publishes, and an editable copy carrying an accredited laboratory's letterhead is worth more to a counterfeiter than to a customer.
Eloralintide storage and stability
Handling as the product record states it, followed by the degradation chemistry this particular sequence is and is not exposed to.
Handling
Store lyophilized peptide at -20°C in a dry, dark environment. Reconstitute in bacteriostatic water. Once reconstituted, store at 2-8°C and use within 30 days. Avoid repeated freeze-thaw cycles. Lyophilized powder is stable at room temperature for shipping and short-term storage.
A residue-level stability profile needs a primary sequence of standard amino acids. This compound's sequence carries modified or non-standard residues, so no finding is derived for it rather than one being estimated from a partial reading. The storage guide covers the general case.
Eloralintide compared with Retatrutide and Tirzepatide
Pharmacological class, half-life, evidence grade, competition status and cost per milligram, side by side.
| Compound | Class | Half-life | Evidence | WADA | Cheapest per mg |
|---|---|---|---|---|---|
| Eloralintidethis page | Weight Loss & Metabolic | Engineered for once-weekly subcutaneous administration | CPhase II Clinical Trials | — | $9.9010mg vial, out of stock |
| Retatrutide | Metabolic / Triple Agonist | ~6 days (allows once-weekly dosing) | BPhase III / NDA Filed | Not prohibited | $4.8520mg vial |
| Tirzepatide | Metabolic / Dual GIP-GLP-1 Agonist | ~5 days (116 hours) | AFDA Approved | Not prohibited | $2.9730mg vial |
| 5-Amino-1MQ | Metabolic / Fat Loss | Unknown in humans; estimated hours based on animal PK | DAnimal/Preclinical Only | Not listed | $4.3010mg vial |
| AOD-9604 | Metabolic / Fat Loss | ~30 minutes | CPhase I–II Clinical Trials | Prohibited | $7.2010mg vial, out of stock |
Evidence grades and half-lives are as recorded in the compound database, which cites its own sources on each compound page. Per-milligram prices are the cheapest strength each compound is currently listed at, in US dollars, and an out-of-stock note means that figure is not purchasable today. Cross-trial comparisons of efficacy are not comparisons: no head-to-head trial exists for most of these pairs.
Eloralintide in Canada
Price in Canadian dollars, where the parcel ships from, and how long it takes.
Price in CAD
CA$141
The figure charged, not a converted estimate
Ships from
British Columbia
A domestic parcel, so no import clearance step
Transit
2 to 5 business days
After 1 to 2 business days of handling
Free standard shipping
Over CA$250
A bar set for this market, not converted from the US one
Eloralintide 10mg ships from British Columbia to Canadian addresses, so the parcel never crosses a border. That removes the failure a Canadian buyer of research peptides is usually weighing: an inbound international shipment can be held for import clearance or seized, and a domestic one has no clearance step to be held at.
Shipping is quoted live against the delivery address at checkout rather than estimated here, and both the standard and express tiers show their price and transit window before a payment method is chosen. The figure the page shows is the figure the rail charges: all three settlement rails price shipping through the same functions the quote does.
The Canadian figure above is not a loose conversion. Each product's US dollar base is chosen so that the live conversion lands on the Canadian shelf price set for this market, and the result is pushed up to a whole dollar rather than left carrying cents, so one figure serves the page, the feed and every payment rail. See the shipping policy for carriers and cut-off times, and the legal position on research peptides in Canada for the regulatory picture.
Eloralintide Mechanism of Action
Eloralintide is a long-acting agonist at the amylin receptor, developed under the code LY3841136. Amylin is a 37 amino acid hormone co-secreted with insulin from pancreatic beta cells, and it acts in the hindbrain, principally at the area postrema, to promote meal termination. It is a satiation signal rather than an incretin, and that places eloralintide in a different pharmacological class from the GLP-1 and GIP agonists it is usually discussed alongside.
The word that matters in its description is selective. The amylin receptors are not standalone proteins: they are formed when the calcitonin receptor associates with one of three receptor activity-modifying proteins, producing AMY1, AMY2 and AMY3. Because the calcitonin receptor is the shared core, an amylin analogue can easily also activate the calcitonin receptor itself. Pramlintide, the earlier amylin analogue, and cagrilintide, the current dual agonist, both carry calcitonin receptor activity. Eloralintide was designed to avoid it.
That selectivity is the pharmacological question the molecule exists to answer. If the benefit of amylin agonism comes from the amylin receptors and the tolerability burden comes partly from calcitonin receptor activity, then a selective agonist should separate the two. Whether it does is what the clinical programme is measuring, and it is why eloralintide is interesting independently of its efficacy numbers.
Amylin receptor engagement
Agonism at receptors formed by the calcitonin receptor in complex with receptor activity-modifying proteins, giving AMY1, AMY2 and AMY3.
Selectivity over the calcitonin receptor
The defining design feature. Earlier amylin analogues also activate the calcitonin receptor itself; this one was engineered not to.
Hindbrain signalling
Amylin acts principally at the area postrema and nucleus tractus solitarius, circuits that govern meal termination rather than appetite in the anticipatory sense.
Satiation rather than incretin action
The signal ends a meal rather than potentiating glucose-dependent insulin secretion, which is what separates this class from GLP-1 and GIP agonists.
Extended duration
Engineered for long action, permitting the weekly administration used in the clinical programme rather than the meal-time dosing native amylin analogues required.
Eloralintide Research Findings
This is an actively developing programme with published phase 1 and phase 2 results. Each entry names the study stage.
Discovery and preclinical characterisation as a selective amylin receptor agonist
The discovery paper characterised the molecule from receptor pharmacology through preclinical models, establishing the selectivity over the calcitonin receptor that distinguishes it from earlier amylin analogues.
In vitroPhase 1 characterisation of a selective long-acting amylin receptor agonist
Phase 1 work reported the pharmacokinetic and pharmacodynamic profile supporting a long-acting selective agonist in humans, which is the basis for the dosing interval used subsequently.
Phase 1 trialWeight reduction in a 48-week phase 2 trial
A 48 week phase 2 trial in adults with obesity reported dose-dependent weight reduction. A 48 week phase 2 is a substantial study for this class and provides duration data most phase 2 programmes do not.
Phase 2 trialAmylin analogues assessed as a class for tolerability
Reviews examining amylin-based pharmacotherapy frame the class as a search for better-tolerated agents of this kind, which is the context that makes calcitonin receptor selectivity worth engineering.
ObservationalAmylin analogues positioned as a major metabolic drug class
Reviews of experimental and clinical data place amylin analogues as the next major class in this therapeutic area, distinct from incretin agonists in mechanism and in side-effect profile.
ObservationalComparative assessment across novel amylin-based therapies
A systematic assessment of novel amylin-based therapies for weight management in adults with overweight or obesity without diabetes compared the agents in development against one another.
ObservationalLong-acting amylin-related peptides reviewed for obesity and type 2 diabetes
A dedicated review of long-acting amylin-related peptides examined the engineering approaches used to extend duration in this class, which is the technical problem eloralintide addresses alongside selectivity.
MechanisticEloralintide Molecular Information
| Class | Long-acting selective amylin receptor agonist |
| Developer Code | LY3841136 |
| Receptor Targets | Amylin receptors AMY1, AMY2 and AMY3 |
| Selectivity | Designed to avoid activity at the calcitonin receptor itself |
| Receptor Composition | Calcitonin receptor in complex with receptor activity-modifying proteins RAMP1, RAMP2 or RAMP3 |
| Parent Hormone | Amylin, also called islet amyloid polypeptide, 37 amino acids |
| Site of Action | Hindbrain, principally the area postrema |
| Regulatory Status | Investigational. Not approved in any jurisdiction |
| Development Stage | Phase 2 completed at 48 weeks |
| Appearance | White lyophilised powder |
Amylin Is Not an Incretin, and the Difference Is Not Cosmetic
Eloralintide is routinely grouped with semaglutide, tirzepatide and retatrutide because all are injectable peptides associated with weight reduction. Mechanistically it belongs to a different family.
GLP-1 and GIP are incretins: gut hormones that potentiate glucose-dependent insulin secretion after a meal, with appetite effects that follow from receptor expression in hypothalamic and hindbrain circuits. Amylin is co-secreted with insulin from the beta cell itself and signals satiation, the termination of an eating episode, acting principally at the area postrema.
The practical implication is that the two classes are candidates for combination rather than substitution, which is why the field is testing amylin analogues alongside incretin agonists rather than against them. It also means the tolerability profiles differ in origin, and a nausea signal in one class does not predict the other.
Why Calcitonin Receptor Selectivity Is the Point
There is no such thing as a standalone amylin receptor protein. The calcitonin receptor associates with one of three receptor activity-modifying proteins, and the resulting complexes are what respond to amylin. Because the calcitonin receptor is the common core, a ligand shaped to fit the complex tends to fit the bare receptor too.
Pramlintide, the first amylin analogue to reach approval, and cagrilintide, the dual agonist currently in development, both carry calcitonin receptor activity. Eloralintide was engineered not to, which makes it a pharmacological experiment as well as a drug candidate.
If the therapeutic effect comes from the amylin receptor complexes and part of the burden comes from the calcitonin receptor, selectivity should widen the gap between them. The clinical programme is the test of that proposition, and it is a cleaner question than most drug development asks.
What a 48-Week Phase 2 Establishes
Most phase 2 obesity trials run 24 to 36 weeks. A 48 week phase 2 provides duration data that shorter studies cannot, including whether the weight curve is still moving at the end of the treatment period and how tolerability behaves over a longer period of exposure.
It remains a phase 2 trial. It is not powered for cardiovascular or other clinical outcomes, it does not establish an approved indication, and its population is defined by the protocol rather than representative of anyone outside it.
The compound has no marketing authorisation anywhere. Material supplied for research is for in-vitro laboratory use only, and nothing summarised here is guidance for use in humans or animals.
Handling and Analytical Considerations
As an investigational molecule there is no pharmacopoeial monograph defining what a compliant preparation contains, so identity and purity rest entirely on the analytical work reported for the specific lot. That makes the stated method and lot identifier on a certificate load-bearing in a way they are not for an established compound.
Amylin itself is notoriously aggregation-prone, which is why it is also called islet amyloid polypeptide, and engineered analogues in this class are designed around that liability. Solution behaviour and storage conditions therefore deserve more attention here than for a sequence with no amyloidogenic parent.
Eloralintide Research FAQ
Eloralintide in Summary
Eloralintide is a long-acting amylin receptor agonist engineered to be selective over the calcitonin receptor, which the earlier analogues in its class are not. Amylin is a satiation signal acting at the hindbrain, not an incretin, so it belongs to a different family from the GLP-1 agonists it is grouped with.
That selectivity makes the programme a test of whether amylin receptor benefit can be separated from calcitonin receptor burden. Published work runs from discovery through phase 1 to a 48 week phase 2, and it is approved nowhere.
Scientific References
Primary literature and public trial registries only. No supplier or retailer pages are cited.
- 1Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: From discovery to clinical candidateBriere DA, Qu H, et al. · Molecular Metabolism · 2025
- 2Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2 trialBillings LK, Hsia S, et al. · The Lancet · 2025
- 3Eloralintide, a selective, long-acting amylin receptor agonist for treatment of obesity: Phase 1 resultsBhattachar S, Tham LS, et al. · Diabetes, Obesity and Metabolism · 2026
- 4Beyond GLP-1: Amylin-based pharmacotherapy and the search for better-tolerated weight-loss drugsFischer SL, Borner T, et al. · Pharmacological Research · 2026
- 5Amylin Analogs: The Next Major Class of Weight Loss Therapy: A Review of Experimental Data and Clinical TrialsAlhazmi A, le Roux CW, et al. · Diabetes, Obesity and Metabolism · 2026
- 6Novel Amylin-Based Therapies for Weight Management in Adults With Overweight or Obesity Without DiabetesKamrul-Hasan ABM, Khalil I, et al. · Endocrinology, Diabetes and Metabolism · 2026
- 7Long-acting amylin-related peptides as therapies for obesity and type 2 diabetesBailey CJ, Flatt PR · Peptides · 2026
Disclaimer
All articles and product information provided on this website are for informational and educational purposes only. The products offered on this website are furnished for in-vitro studies only. These products are not medicines or drugs and have not been approved by the FDA to prevent, treat or cure any medical condition, ailment or disease.
Eloralintide 10mg: frequently asked questions
Answered from the product record and the certificate file. Volta does not answer questions about administration, dosing or protocols.
What is supplied in a 10 mg vial of Eloralintide?
A sealed single-use vial containing 10 mg of Eloralintide as a lyophilized powder. Soluble in bacteriostatic water. No diluent, syringe or other supply is included.
Is Eloralintide supplied for human use?
No. For in-vitro laboratory research by qualified professionals only. Not for human or animal administration. Not a drug, food, cosmetic or dietary supplement. Not intended to diagnose, treat, cure, mitigate or prevent any disease. Volta does not provide dosing, administration or protocol guidance for any material listed.
What purity is this Eloralintide released to?
>99% by HPLC. That figure is a release specification, a threshold Volta sets for every batch, and it is not the same kind of statement as a purity measured by a named laboratory for a named lot.
Is there a certificate of analysis for this Eloralintide vial?
A batch-specific Certificate of Analysis is available for this product on request. It is not published on the site yet: the batch history on the quality page lists the certificates already published, and this vial is covered by the release specification until its own is added there.
How should Eloralintide be stored before reconstitution?
Store lyophilized peptide at -20°C in a dry, dark environment. Reconstitute in bacteriostatic water. Once reconstituted, store at 2-8°C and use within 30 days. Avoid repeated freeze-thaw cycles. Lyophilized powder is stable at room temperature for shipping and short-term storage.
Where does this ship from?
British Columbia, Canada. Canadian orders are domestic, so they clear no customs and pay no import duty. International orders ship from the same facility.
Peptide Tools
More from the research catalogue
Every compound below has its own specification, batch number and certificate page, whether or not a vial is in stock today. Supplied for laboratory research use only.
Related research compounds
- HGH Fragment 176-191 5mgrestocking
- L-Carnitine 5000mgrestocking
- Lipo-C 10mlrestocking
- Lipo-C with B12 10mlrestocking
- Melanotan I 10mgrestocking